Kate and Torigoe (5) described a new tumor-associated antigen (Ta-4) in squamous cell carcinoma of the uterine cervix as a protein with an apparent molecular mass of 48 000 Da. The isoelectric focusing method revealed 14 subfractions of Ta-4. The most nearly neutral fraction was purified and designated "SOC antigen." Later Kate et al. (5, 6) developed a radioimmunoassay based on a polyclonal antiserum that measures this antigen in the circulation. Initial studies indicate increased concentrations of SOC in patients with squamous cell carcinoma of the cervix (6) (7) (8) .
As yet, experience with this new tumor marker is confined almost exclusively to cervical cancer. Our aim here was to evaluate SCC in the sera of patients with tumors of several different histological types and in benign disease, to determine its sensitivity and specificity.
Materials and Methods
We measured SOC in the sera of 214 patients with benign diseases and 251 patients with cancer.
The first group included 30 patients with lung disease (16 with infectious diseases, 14 with chronic diseases), 20 (6, 9) . In summary, 100 L of serum sample or SOC standard, 200 L of iodine-labeled Ta-4 (1251), and 100 L of anti-Ta-4 serum were incubated for 24 h at room temperature.
Later, 500 tL of second antibody (goat anti-rabbit gamma-globulin) was added and the mixture was left at room temperature for 10 mm. After centrifugation (20 mm, 3000 rpm, 400), the supernates were aspirated and the radioactivity in the pellet was counted in a gamma counter. All standards and samples were assayed in duplicate. Sensitivity of the assay was 1.5 ug/L with an average intra-assay CV of 8.5% and interassay CV of 9.35%.
Creatinine was measured in an aliquot of the same serum sample used for SOC determination in all subjects of the control group and in 150 cases with benign disorders. It was also determined in all cancer patients, and cases with abnormal values were excluded. We used the kinetic Jaff#{233} method; values <133 j.unolJL were considered to be within normal limits.
For statistical analysis we used the Kolmogorov test and the Mann-Whitney U and Student's t-tests for quantitative results and the chi-square test for qualitative results. In evaluating the results we considered "sensitivity" as the ratio between the number of patients with above-normal SOC concentrations (>2.5 pg/L) and active neoplasms and the total number of patients with active tumors (excluding the cases with no evidence of clinical disease). "Specificity" was calculated by dividing the number of patients with non-malignant diseases and SOC negativity by the total number of cases of benign diseases.
Results
Of the healthy subjects, 63.7% had no detectable SCC in their sera, i.e., <1.5 pg/L. Because 97.1% of them had values of SOC <2.5 ugfL, this value was considered to be the upper limit of normal.
SCC specificity in patients with benign diseases was 71%. Higher SOC values were found in 29.0% of patients with benign diseases, being highest in patients with renal failure (64%), lung pathologies (40%), and head-and-neck diseases (21.2%) ( Table 1 ). In patients with benign lung diseases, there were no statistically significant differences between infectious and non-infectious etiologies (Table 1 ). In patients with head-and-neck diseases, SOC values were significantly higher (P <0.01) in patients with benign tumors than in those with other diseases. Table 2 summarizes our data on SOC in sera of patients with renal failure. The more severe the renal disease (the criterion being the values for serum creatinine), the higher the proportion of patients with abnormal values for this antigen. There were no differences in serum SOC values among the different groups of patients with impaired renal function, although patients with serum creatinine concentrations <354 pmol/L had lower values for SOC in serum than did those with higher concentrations.
When we excluded those patients with benign disorders who had renal failure or creatinine values >133 mol/L, the proportion of false positives in these patients decreased to 8.9% (Table 3) . Disorders more frequently associated with false-positive results were lung diseases (30.7%) and benign tumors of the head and neck (46.2%).
Abnormally high SOC concentrations were found in 41% (Table  5) . Among squamous carcinomas, the highest values were found in cervical carcinomas, mainly for those in stages Ill-N.
DIscussion
The use of tumor markers has increased rapidly in the last few years because new antigens have been discovered that have been applied to the study of different types of tumors (1-4,10) .
In general, tumor markers are not useful for diagnostic purposes because of their low sensitivity and However, their usefulness in the follow-up of neoplastic patients has been widely demonstrated, mainly for monitoring of the efficacy of therapy and sometimes for early detection of recurrence (12-16). When a new tumor marker is being evaluated, it is very important to study its specificity, i.e., to know which diseases are associated with increased values. Most of the currently available tumor markers show increased values associated with some benign pathologies (10, (12) (13) (14) (15) (16) (17) .
SOC is a tumor marker first described by Kato et al. (5) (6) (7) in patients with cervical squamous cell carcinoma. Initially, the presence of 5CC, demonstrated by immunohistochemical procedures, was thought to be specific for squamous cell carcinomas, but later it was also detected in normal squamous epithelium and in benign tumors of epithelial origin (18). Our detection of 5CC in serum of patients with benign disease confirms its release in situations other than malignancies of epidermoid origin. Renal failure was the benign disease we found to be associated most frequently with high 500 concentrations. Although no statistically significant correlation was found between SOC and creatinine concentrations in serum, the percentage of abnormal values for serum SCO increased in proportion to the degree of renal damage (Table 2) . When we excluded patients with renal failure or with abnormal creatinine values, SOC specificity increased notably: from 71% to 91.1%. In only 8.9% of cases without renal failure did we find abnormal values for 500, in contrast with Our results for patients with active cancer indicate that this antigen is commonly increased in squamous cell carcinomas. Only 9.3% of non-epidermoid tumors had abnormal values for this tumor marker, in contrast to 57.7% with epidermoid tumors (P <0.001). Six of the seven patients with abnormal SOC concentrations and non-squamous cell carcinoma had lung cancer. Moreover, a high rate of falsely positive results was found among patients with benign lung diseases. These results seem to indicate that SOC is present in normal lung epithelium, being released in some benign and neoplastic conditions other than squamous cell carcinomas.
Nevertheless, SOC can be a useful tumorassociated antigen in lung cancer, because values are abnormal in over half of squamous tumors (Table 4 ). There are no specific tumor markers for use in the management of lung cancer. Assay of SOC in such patients, together with other markers related to some histological type, such as neuron-specific enolase in small-cell carcinomas or CA 125 in large-cell undifferentiated carcinomas, can be used to manage lung cancer (21-24) .
The sensitivity of the SOC test in squamous cell carcinoma is similar irrespective of tumor origin and is related to the clinical stage. In head-and-neck carcinomas, test sensitivity in grade T1-2 is about 45.5%, increasing to 60% in T3-4 tumors and to 73.7% in patients with local or distant recurrence ( Table 5) . Similar results were obtained for cervical carcinomas, confirming previous reports (5 -9) . Moreover, in cervical carcinoma-from which SOC was originally isolated-values were higher than in other squamous tumors.
We conclude that SOC is not a specific tumor marker for squamous cell carcinoma (specificity 7 1%), because values are also abnormal in benign diseases of the head and neck and of the lungs, and especially so in renal failure. However, the higher sensitivity of SOC in squamous cell carcinomas than in other histological types and its relation to tumor extension suggest its possible application in management of patients with squamous cell carcinoma, particularly cervical carcinomas.
